SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma
T cells taken from patients and engineered to recognise the MAGE-A4 protein shrank tumours in about four in ten patients with advanced synovial sarcoma, leading to the first approval of a TCR T-cell therapy for any solid cancer.
Single-arm phase 2 trial of 52 patients (44 with synovial sarcoma, 8 with myxoid/round cell liposarcoma) who were HLA-A*02 positive with MAGE-A4-expressing tumours, previously treated with anthracycline or ifosfamide, treated with a single infusion of afamitresgene autoleucel (afami-cel), autologous T cells expressing an affinity-enhanced MAGE-A4-specific T-cell receptor, after lymphodepleting chemotherapy. Primary endpoint was objective response rate.
The response rate was 37% overall and 39% in synovial sarcoma, with a median duration of response of about 12 months. Cytokine release syndrome occurred in about 70% but was mostly low grade. It led to FDA accelerated approval in 2024 (Tecelra), the first TCR-T and the first engineered cell therapy approved for a solid tumour.
- Objective response 37% overall (19 of 52); 39% in synovial sarcoma and 25% in myxoid/round cell liposarcoma.
- Median duration of response about 12 months; median PFS about 3.8 months and median OS about 15 months in a heavily pretreated population.
- Cytokine release syndrome in about 70% of patients, grade 3 in around 2%; cytopenias were common after lymphodepletion.
- Eligibility required both HLA-A*02 genotype and MAGE-A4 expression, satisfied by roughly a third of screened synovial sarcoma patients.
- Manufacturing success was high but the process took several weeks per patient.
Patients with advanced synovial sarcoma, a rare cancer of young adults with few effective drugs, now have an approved cell therapy that produces responses lasting about a year in a substantial minority, if their tissue type and tumour antigen match. It proves that engineered T cells can work against a solid tumour when a good target is present, which had been elusive. It is not a cure for most, requires specialised centres, and only a minority of patients are eligible.
- Single-arm trial with a response-rate endpoint; no randomised comparison and OS benefit is unproven.
- Restricted to HLA-A*02-positive patients, which excludes many people of non-European ancestry.
- Responses are usually not durable beyond a year; mechanisms of relapse (antigen loss, T-cell exhaustion) are being studied.
- Very high cost and complex logistics for a rare indication.
Pages like this
not linked directly; found by shared links- Key paperSPEARHEAD-1: afami-cel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma
Shares Adaptimmune, Afamitresgene autoleucel, Objective response rate (ORR), TCR-T cell therapy.
- IdeaExtending sarcoma TCR-T beyond HLA-A*02
Shares MAGE-A4, Afamitresgene autoleucel, TCR-T cell therapy, Rare and paediatric cancers without markets.
- CompanyUS WorldMeds
Shares Afamitresgene autoleucel, Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- CompanyTScan Therapeutics
Shares MAGE-A4, TCR-T cell therapy.
- IdeaLet adolescents from age 12 into adult trials when the cancer biology is the same
Shares Trials do not represent the people who get cancer, Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- RoadmapCell therapy roadmap: CD19 CAR-T → solid tumours → in vivo CAR
Shares MAGE-A4, Afamitresgene autoleucel, TCR-T cell therapy, Manufacturing cost and time for living and radioactive medicines.
- InstitutionCentre Léon Bérard
Shares Jean-Yves Blay, Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- TermHLA-A*02:01 restriction
Shares Afamitresgene autoleucel, TCR-T cell therapy, Sarcomas (soft tissue, bone, GIST).